Veracyte, Inc.
47.93USD
+1.8900 (+4.11%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VCYT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.41▼ | $0.44 | 0 | 1 |
| Next quarter | $0.45▼ | $0.45 | 0 | 3 |
| Current year | $1.91▲ | $1.8 | 1 | 1 |
| Next year | $1.94▲ | $1.89 | 1 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.43 | $0.54 | +0.11 (+25.1%) |
| 2026-03-31 | $0.33 | $0.52 | +0.19 (+56.0%) |
| 2025-12-31 | $0.41 | $0.53 | +0.12 (+29.8%) |
| 2025-09-30 | $0.32 | $0.51 | +0.19 (+59.5%) |
118 ratings from 21 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Freedom Capital Markets | Maintained | Buy | $66 | Sep 15, 2026 |
| UBS | Maintained | Buy | $52 $65 | Sep 9, 2026 |
| Piper Sandler | Maintained | Overweight | $66 $54 | Aug 4, 2026 |
| Stephens & Co. | Maintained | Overweight | $68 $55 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Underweight | $47 $44 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Hold | $60 $50 | Aug 3, 2026 |
| Needham | Maintained | Buy | $57 $69 | Jul 31, 2026 |
| Needham | Maintained | Buy | $57 $69 | Jul 30, 2026 |
| Piper Sandler | Initiated | Overweight | $66 | Jul 15, 2026 |
| Canaccord Genuity | Maintained | Hold | $42 $60 | Jul 14, 2026 |
| Morgan Stanley | Maintained | Underweight | $37 $47 | Jul 9, 2026 |
| Guggenheim | Maintained | Buy | $45 $65 | Jun 29, 2026 |
| Needham | Maintained | Buy | $48 $57 | Jun 1, 2026 |
| Needham | Reiterated | Buy | $48 | May 28, 2026 |
| Canaccord Genuity | Maintained | Hold | $40 $42 | May 6, 2026 |
| UBS | Maintained | Buy | $48 $52 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $43 $40 | Apr 20, 2026 |
| Jefferies | Initiated | Buy | $45 | Apr 13, 2026 |
| Needham | Maintained | Buy | $48 | Apr 1, 2026 |
| Guggenheim | Maintained | Buy | $50 $45 | Mar 30, 2026 |
| Morgan Stanley | Maintained | Underweight | $48 $37 | Mar 6, 2026 |
| Needham | Maintained | Buy | $44 $48 | Feb 26, 2026 |
| Guggenheim | Maintained | Buy | $45 $50 | Jan 5, 2026 |
| Morgan Stanley | Maintained | Underweight | $40 $48 | Dec 2, 2025 |
| Morgan Stanley | Maintained | Underweight | $28 $40 | Nov 11, 2025 |
121 filings from 23 insiders · 10 buy / 15 sell over 6m
Officers and directors of VCYT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bhanji MunaDirector | Sell | 1.9k | $43.70 | $81k | Oct 19, 2026 |
| Leite JohnOfficer, Global Chief Commercial Off | Sell | 4.0k | $40.00 | $161k | Sep 21, 2026 |
| Holstein JensDirector | Sell | 5.0k | $40.95 | $205k | Sep 14, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Sell | 10.4k | $42.89 | $446k | Sep 4, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Sell | 2.7k | $43.66 | $118k | Sep 4, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Sell | 2.5k | $42.81 | $106k | Sep 4, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Sell | 1.2k | $43.71 | $51k | Sep 4, 2026 |
| McGuire AnnieOfficer, EVP, General Counsel | Sell | 2.2k | $42.79 | $92k | Sep 4, 2026 |
| McGuire AnnieOfficer, EVP, General Counsel | Sell | 1.1k | $43.67 | $48k | Sep 4, 2026 |
| Stapley MarcDirector; Officer, Chief Executive Officer | Tax | 8.8k | $44.88 | $394k | Sep 2, 2026 |
| Wygant JonathanOfficer, VP, Chief Accounting Officer | Tax | 1.4k | $44.88 | $61k | Sep 2, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Tax | 3.6k | $44.88 | $163k | Sep 2, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Tax | 3.6k | $44.88 | $162k | Sep 2, 2026 |
| McGuire AnnieOfficer, EVP, General Counsel | Tax | 3.2k | $44.88 | $144k | Sep 2, 2026 |
| Leite JohnOfficer, Global Chief Commercial Off | Tax | 4.0k | $44.88 | $178k | Sep 2, 2026 |
| Bhanji MunaDirector | Sell | 1.9k | $42.97 | $80k | Sep 1, 2026 |
| EASTHAM KARINDirector | Sell | 3.7k | $52.78 | $197k | Jun 18, 2026 |
| EASTHAM KARINDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| JONES EVANDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| EPSTEIN ROBERT SDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
No analyst notes on VCYT yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 1 mo ago | 2 | 9 | 1 | 1 | 0 | Buy2.08 |
| 2 mo ago | 2 | 8 | 1 | 1 | 0 | Buy2.08 |
| 3 mo ago | 2 | 7 | 1 | 1 | 0 | Buy2.09 |
Members whose judged calls on VCYT have played out most reliably.
No settled calls on VCYT yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice